ELTROMBOPAG TEVA 50 mg, film-coated tablet scored 28 tablets
Active ingredients: Eltrombopag, Eltrombopag olamine
Commercialized according to BDPMDispensing in France: Prescription only
Film-coated tablet scored28 tabletsorale
No current ANSM shortage notice is included
Package details
Original BDPM fields are shown in French.
- Official name
- ELTROMBOPAG TEVA 50 mg, comprimé pelliculé sécable
- Pharmaceutical form
- comprimé pelliculé sécable
- Route of administration
- orale
- Presentation description
- plaquette(s) OPA : polyamide orienté aluminium PVC de 28 comprimé(s)
- Marketing authorisation holder
- TEVA SANTE
- Reimbursement according to BDPM
- 65 %
- Approval for use in healthcare institutions
- oui
- Commercialization declaration date
- 17 Sept 2025
- Prescription and dispensing conditions
- Prescription only
- List I: prescription-only medicine
- Requires special monitoring during treatment
- Prescribed by a hospital doctor
- Prescribed by specialists only
- Enhanced ANSM monitoring
- No
BDPM identifiers
CIS
63946583CIP73031466CIP133400930314661Composition in BDPM
| Component | Amount per unit | Source type |
|---|---|---|
| ELTROMBOPAG OLAMINEcomprimé | — | SA |
| ELTROMBOPAGcomprimé | 50 mg · un comprimé | FT |
Information is based on BDPM data and is for reference only. Consult a doctor before use.
Similar medicines
Similar medicines are listed using the official BDPM catalog. Availability must be checked separately. Consult a doctor or pharmacist before switching medicines.